21st July 2020
Rivastigmine patches switched from 'amber' to 'green' (section 4.11)

20th July 2020
Verkazia® (ciclosporin 1mg/ml) eye drops added as a 'red' drug for the treatment of severe vernal keratoconjunctivitis (VKC) in children from 4 years of age and adolescents (section 11.8.3)

3rd July 2020
Chloroprocaine (Ampres®) added as a 'red' drug (section 15.2.3)

1st July 2020
Fremanezumab added as a 'red' drug for migraine prevention as per NICE TA631 (section 4.7.5.2)
Ulcerative colitis added as an indication for ustekinumab as per NICE TA633 (section 1.5.3.1)
Voretigene neparvovec added as a 'red' drug for inherited retinal dystrophies caused by RPE65 gene mutations, as per NICE HST11 (section 11.8.3)

27th May 2020
Ulipristal acetate 5mg (Esmya®) removed following MHRA recall (section 6.4.1.6)

6th March 2020
Pentosan polysulfate sodium added as a 'red' drug for bladder pain syndrome, as per NICE TA610 (section 7.4.3)
Cannabidiol (Epydiolex®) added as a 'red' drug for Dravet and Lennox-Gastaut syndromes, as per NICE TA614 and NICE TA615 (section 4.8.1.3)
Sotagliflozin added as an 'amber' drug for type 1 diabetes in combination with insulin, as per NICE TA622 (section 6.1.2.5)

25th February 2020
Methyl-5-aminolevulinate cream (Metvix®) added as a 'red' drug for Dermatology use (section 13.8.2)

4th February 2020
Eslicarbazepine as an 'amber' drug for the treatment of epilepsy (section 4.8.1.3)

27th January 2020
Ingenol mebutate (Picato®) gel removed. Marketing Authorisation suspended pending investigations regarding safety (section 13.8.2)

27th December 2019
Retigabine removed (discontinued) section 4.8.1.3

19th December 2019
Over active bladder Formulary updated as follows (section 7.4.2)
Solifenacin has replaced tolterodine MR as a second-line option (first-line where compliance significantly improved by once-daily administration)
Oxybutynin tablets, tolterodine MR, and trospium MR have been removed.
Penthrox® added as a 'red' drug for use in ED only (section 15.1.2)
Mydrane® added as a 'red' drug restricted for patients where mydriasis is inadequate with topical therapy prior to cataract surgery (section 11.5)

29th November 2019
GlucoRx Safety Pen Needles added for use by district / community nurse use (section 6.1.1.1)

28th November 2019
Olopatadine eye drops added as a second-line option when OTC sodium cromoglicate is ineffective (section 11.4.3)
Ketofall® eye drops added as a third-line option when OTC sodium cromoglicate is ineffective and the patient has a documented preservative allergy (section 11.4.3)
Escitalopram added as a second-line SSRI option when citalopram is not tolerated (section 4.3.3)
Eplerenone switched from amber to green as a second-line option for heart failure patients when spironolactone is not tolerated (section 2.2.3)
Bunov® has replaced Butec® as the weekly buprenorphine transdermal patch of choice (section 4.7.3)

15th November 2019
Fencino®, Mezolar® and Matrifen® specified as the lower cost fentanyl patches of choice where a patch is definitely required (section 4.7.3)

8th November 2019
Chronic sialorrhoea added as an indication for Xeomin (botulinum neurotoxin type A) as per NICE TA605 (section 4.9.3.1)
Lanadelumab added for preventing recurrent attacks of hereditary angioedema, as per NICE TA606 (section 3.4.2.2)
Prevention of atherothrombotic events in people with coronary or peripheral artery disease added as an indication for rivaroxaban, as per NICE TA607 (section 2.8.2)

6th November 2019
Testavan® 20mg/g transdermal gel has replaced Tostran® 2% gel as the transdermal testosterone of choice (section 6.4.2.1)

19th September 2019
Risankizumab added for moderate to severe plaque psoriasis, as per NICE TA596 (section 13.5.3.2)

16th September 2019
Hydrocortisone 10mg tablets to be prescribed as Hydventia brand (section 6.3.1)

6th September 2019
Emollient Formulary updated (section 13.2)
Psoriasis biologics pathway added (section 13.5.3.2)
Inflammatory Bowel Disease (IBD) biologics pathway added (section 1.5.3.1)

28th August 2019
Loteprednol 0.5% eye drops approved as a 'red' drug for restricted use in post-operative patients (section 11.4.1)

13th August 2019
Aliskiren removed following publication of NHS Clinical Commissioners document: Items which should not routinely be prescribed in primary care: Guidance for CCGs Version 2, June 2019

31st May 2019
Psoriasis added as an indication for certolizumab as per NICE TA574 (section 13.5.3.2)
Tildrakizumab added as an option for the treatment of psoriasis as per NICE TA575 (section 13.5.3.2)

29th May 2019
Insulin Formulary updated (section 6.1.1)
Summary of changes:

  • Semglee® has replaced Abasaglar® as the long-acting analogue insulin of choice (pre-filled pens only)
  • Insulin Lispro Sanofi® has replaced Apidra® as the short-acting insulin of choice
  • Insuman Comb 25® has replaced Humulin M3® as the biphasic human insulin of choice
  • Insuman Basal® has replaced Humulin I® as the long-acting human insulin of choice

3rd May 2019
Wound Management Formulary added

5th April 2019
Opicapone added as a 'red' drug second-line to entacapone (section 4.9.1.4)
Guanfacine added as a 'red' drug second-line to atomoxetine (section 4.4)

1st April 2019
Ertugliflozin (SGLT2 inhibitor) added, as per NICE TA572 (section 6.1.2.5)

19th March 2019
SLS requirements for erectile dysfunction updated and generic tadalafil added for PRN use only (section 7.5.1)
Benralizumab added as a 'red' drug for severe eosinophilic asthma, as per NICE TA565 (section 3.4.1.3)

7th March 2019
Lubiprostone removed following manufacturer's discontinuation (section 1.6.7).

31st January 2019
Semaglutide added a the weekly GLP-1 agonist of choice (section 6.1.2.6)
Kyleena® added to replace Jaydess® as the low-dose levonorgestrel IUS of choice (section 7.3.5)

29th January 2019
Donepezil, galantamine, rivastigmine capsules, and memantine switched from 'amber' to 'green' drugs (section 4.11)

28th December 2018
Insulin Lispro Sanofi® added to the list of 'alternative' insulin preparations on the Insulin Formulary

30th November 2018
Flexitol® skin and heel balm (urea 12.5% and 25% respectively) added as an alternative to salicylic 2% ointment where a cream base would be better tolerated, and first-line ahead of unlicensed salicylic acid 5% and 10% preparations (section 13.2.4.5)

29th November 2018
Psoriatic arthritis added as an indication for tofacitinib as per NICE TA543 (section 10.1.3.5)
Ulcerative colitis added as an indication for tofacitinib as per NICE TA547 (section 1.5.3.1)

23rd October 2018
Combisal added to replace Sereflo and AirFluSal as the fluticasone/salmeterol MDI of choice (section 3.2.3.1)

15th October 2018
Naloxegol switched from 'red' to 'green' . Prucalopride and lubiprostone switched from 'amber' to 'green' (section 1.6).

10th September 2018
Xaggitin XL specified as the preferred brand of methylphenidate MR (section 4.4)

17th August 2018
Ixekizumab added as a 'red' drug for psoriatic arthritis, as per NICE TA537 (section 10.1.3.5)
Dupilumab added as a 'red' drug for atopic dermatitis, as per NICE TA534 (section 13.5.3.2)

25th July 2018
Noqdirna® (desmopressin oral lyophilisate) added for idiopathic nocturnal polyuria (section 6.5.2.1)

11th July 2018
Guselkumab added as a 'red' drug for psoriasis, as per NICE TA521 (section 13.5.3.2)

29th June 2018
Primary Care Antibiotic Guidelines updated (chapter 5)
Erectile Dysfunction section re-worded regarding generically available phosphodiesterase type-5 inhibitors (section 7.5.1)

27th June 2018
Asthma inhaler guideline updated (chapter 3)
COPD inhaler guideline updated (chapter 3)

18th June 2018
Teriparatide switched from 'amber' to 'red', section 6.6.1.

5th June 2018
Fluphenazine decanoate removed due to manufacturer discontinuing production, section 4.2.2

18th April 2018
Giant cell arteritis added as an indication for tocilizumab, as per NICE TA518, section 10.1.3.5

3rd April 2018
Acarizax® oral lyophysilate added as a 'red' drug for the treatment of house dust mite allergy, section 3.4.1.3

27th March 2018
Renacet® (Calcium acetate) tablets added as an 'amber' drug for use as a phosphate binder in renal impairment, section 9.6.2

21st March 2018
Brodalumab added as a 'red' drug for moderate to severe plaque psoriasis, as per NICE TA511, section 13.5.3.2

10th January 2018
Non-radiographic axial spondyloarthritis added as an indication for golimumab, as per NICE TA497, section 10.1.3.5

8th January 2018
Mecysteine removed as no longer available (section 3.7)

BEST CARE FOR EVERYONE